|
|||||
|
|
Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment,Reporting and Tracking program |
|
| Authors: | Taufiq Salahuddin MD Vanessa Richardson BA Demetria M McNeal PhD Kamal Henderson MD Paul L Hess MD Sridharan Raghavan MD David R Saxon MD Javier A Valle MD Stephen W Waldo MD P Michael Ho MD Gregory G Schwartz MD |
| Institution: | 1. Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA;2. University of Colorado School of Public Health, Aurora, Colorado, USA;3. University of Colorado School of Medicine, Aurora, Colorado, USA;4. Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA
University of Colorado School of Medicine, Aurora, Colorado, USA;5. University of Colorado School of Medicine, Aurora, Colorado, USA Section of Hospital Medicine, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA;6. University of Colorado School of Medicine, Aurora, Colorado, USA Endocrinology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA;7. Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA University of Colorado School of Medicine, Aurora, Colorado, USA Denver-Seattle Center of Innovation for Veteran Centered and Value Driven Care, Denver, Colorado, USA |
| Abstract: | |
| Keywords: | cardiovascular disease empagliflozin GLP-1 liraglutide SGLT2 inhibitor type 2 diabetes |